Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mucosal microRNAs relate to age and severity of disease in ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The optimal cut-off value in fit-based colorectal cancer screening: An observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Metastatic colorectal cancer (mCRC) is treated with cetuximab 250 mg/m2 administered weekly over 1 hour or biweekly (q2w) over 3.5 hours when combined with irinotecan. This prospective study investigated cetuximab 500 mg/m2 plus irinotecan 180 mg/m2 administered q2w over 1.5 hours independent of RAS or BRAF mutation status in mCRC patients in a third-line setting. The intention-to-treat population included 181 patients. No patients had complete response, 18% had partial responses (PR) and 48% stable disease (SD). For cetuximab, a relative dose intensity of ≥90% was reached in 78% and for irinotecan in 67% of the patients. Grade 3 to 4 toxicities were pain (17%), fatigue (9%), neutropenia (8%), diarrhea (8%), rash (8%), infection (7%) and hypersensitivity (3%). No deaths occurred. Next-generation sequencing in 96.7% of the patients revealed that 50.3% had RAS and BRAFV600E wild type (WT), with a mutation type (MT) in 45.1% of the RAS and 4.4% of the BRAFV600E genes. In patients with RAS-WT and RAS-MT tumors, a PR was obtained in 32% and 4% (P = .000003) and an SD in 43% and 53%, respectively, with a superior PFS (6.2 vs 3.7 months; hazard ratio [HR] 2.12, P = .00001) and OS (12.9 vs 8.8 months; HR 1.71, P = .0008). Treatment efficacy was poor in 7.4% of patients with an RAS mutation outside KRAS exon 2 and in 38% of patients with KRAS exon 2 mutations. Administration of cetuximab and irinotecan q2w, shortening treatment time from 3.5 to 1.5 hours, is recommended as standard therapy.

Original languageEnglish
JournalInternational Journal of Cancer
Pages (from-to)1
Number of pages15
ISSN0020-7136
DOIs
Publication statusPublished - Jan 2021

    Research areas

  • cetuximab, colorectal cancer, irinotecan, RAS-mutation, biweekly

ID: 61898703